Chris Schott
Stock Analyst at JP Morgan
(3.84)
# 534
Out of 5,182 analysts
156
Total ratings
59.26%
Success rate
6.54%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Overweight | $125 → $135 | $110.23 | +22.47% | 8 | Apr 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $225 → $250 | $225.34 | +10.94% | 1 | Mar 5, 2026 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $22.09 | +26.75% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $868.27 | +49.72% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $744.44 | +27.61% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $31.26 | +11.96% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $11.49 | +56.66% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $13.16 | -8.81% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $117.87 | +69.68% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $574.95 | +34.79% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $260 | $197.38 | +31.73% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $145 → $150 | $127.75 | +17.42% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $12.57 | +11.38% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $180.67 | -3.14% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $49.65 | -15.41% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $340.18 | -20.63% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.79 | +26.91% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $14.81 | -5.47% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.84 | +497.83% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.58 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $57.78 | +34.99% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.12 | +795,544.89% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.07 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.55 | +95.69% | 3 | Nov 2, 2018 |
Merck & Co.
Apr 6, 2026
Maintains: Overweight
Price Target: $125 → $135
Current: $110.23
Upside: +22.47%
Johnson & Johnson
Mar 5, 2026
Maintains: Neutral
Price Target: $225 → $250
Current: $225.34
Upside: +10.94%
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $22.09
Upside: +26.75%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $868.27
Upside: +49.72%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $744.44
Upside: +27.61%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $31.26
Upside: +11.96%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $11.49
Upside: +56.66%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $13.16
Upside: -8.81%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $117.87
Upside: +69.68%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $574.95
Upside: +34.79%
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $197.38
Upside: +31.73%
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $127.75
Upside: +17.42%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.57
Upside: +11.38%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $180.67
Upside: -3.14%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $49.65
Upside: -15.41%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $340.18
Upside: -20.63%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.79
Upside: +26.91%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $14.81
Upside: -5.47%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.84
Upside: +497.83%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.58
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $57.78
Upside: +34.99%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.12
Upside: +795,544.89%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.07
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.55
Upside: +95.69%